These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26231159)

  • 41. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
    Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
    Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective JAK inhibitors.
    Dymock BW; Yang EG; Chu-Farseeva Y; Yao L
    Future Med Chem; 2014; 6(12):1439-71. PubMed ID: 25329199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
    Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
    Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of lipopolysaccharide-induced inducible nitric-oxide synthase expression through the nuclear factor-kappaB pathway and interferon-beta/tyrosine kinase 2/Janus tyrosine kinase 2-signal transducer and activator of transcription-1 signaling cascades by 2-naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a new synthetic isoquinoline alkaloid.
    Kim HJ; Tsoyi K; Heo JM; Kang YJ; Park MK; Lee YS; Lee JH; Seo HG; Yun-Choi HS; Chang KC
    J Pharmacol Exp Ther; 2007 Feb; 320(2):782-9. PubMed ID: 17108235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
    Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
    Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
    Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.
    Menet CJ; Fletcher SR; Van Lommen G; Geney R; Blanc J; Smits K; Jouannigot N; Deprez P; van der Aar EM; Clement-Lacroix P; Lepescheux L; Galien R; Vayssiere B; Nelles L; Christophe T; Brys R; Uhring M; Ciesielski F; Van Rompaey L
    J Med Chem; 2014 Nov; 57(22):9323-42. PubMed ID: 25369270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells.
    Ide H; Nakagawa T; Terado Y; Kamiyama Y; Muto S; Horie S
    Biochem Biophys Res Commun; 2008 May; 369(2):292-6. PubMed ID: 17920038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.
    Sohn SJ; Barrett K; Van Abbema A; Chang C; Kohli PB; Kanda H; Smith J; Lai Y; Zhou A; Zhang B; Yang W; Williams K; Macleod C; Hurley CA; Kulagowski JJ; Lewin-Koh N; Dengler HS; Johnson AR; Ghilardi N; Zak M; Liang J; Blair WS; Magnuson S; Wu LC
    J Immunol; 2013 Sep; 191(5):2205-16. PubMed ID: 23894201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
    Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B
    Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
    Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
    ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tyk2 mediates effects of urokinase on human vascular smooth muscle cell growth.
    Patecki M; von Schaewen M; Tkachuk S; Jerke U; Dietz R; Dumler I; Kusch A
    Biochem Biophys Res Commun; 2007 Aug; 359(3):679-84. PubMed ID: 17548050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. De Novo Fragment Design for Drug Discovery and Chemical Biology.
    Rodrigues T; Reker D; Welin M; Caldera M; Brunner C; Gabernet G; Schneider P; Walse B; Schneider G
    Angew Chem Int Ed Engl; 2015 Dec; 54(50):15079-83. PubMed ID: 26486226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
    Elsayed MS; El-Araby ME; Serya RA; El-Khatib AH; Linscheid MW; Abouzid KA
    Eur J Med Chem; 2013 Mar; 61():122-31. PubMed ID: 23063746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.